| Literature DB >> 24034279 |
Johannes Hofland1, Leo J Hofland, Peter M van Koetsveld, Jacobie Steenbergen, Wouter W de Herder, Casper H van Eijck, Ronald R de Krijger, Francien H van Nederveen, Maarten O van Aken, Johannes W de Groot, Thera P Links, Frank H de Jong, Richard A Feelders.
Abstract
BACKGROUND: Adrenal Cushing's syndrome caused by ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) can be accompanied by aberrant responses to hormonal stimuli. We investigated the prevalence of adrenocortical reactions to these stimuli in a large cohort of AIMAH patients, both in vivo and in vitro.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24034279 PMCID: PMC3847204 DOI: 10.1186/1750-1172-8-142
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Characteristics of AIMAH patients evaluated
| Male/female | 9/26 |
| Age (years) | 56.1±9.8 |
| Adrenalectomy | 22 (63%) |
| Hypercortisolism | |
| - SCS | 13 (37%) |
| - CCS | 22 (63%) |
| Diameter adrenal (mm) | |
| - left SCS | 31.7±10.1 |
| - left CCS | 46.1±16.9* |
| - right SCS | 27.2±8.8 |
| - right CCS | 43.6±17.0* |
| Hypertension | |
| - SCS | 7 (54%) |
| - CCS | 17 (77%) |
| Diabetes mellitus | |
| - SCS | 6 (46%) |
| - CCS | 6 (29%) |
| Bone loss | |
| - Osteopenia | |
| • SCS | 4 (31%) |
| • CCS | 4 (18%) |
| - Osteoporosis | |
| • SCS | 5 (42%) |
| • CCS | 5 (24%) |
| Midnight cortisol (nmol/l) | |
| - SCS | 184±80 |
| - CCS | 319±145* |
| Urinary free cortisol (nmol/24h) | |
| - SCS | 481±121 (0% > URL) |
| - CCS | 1048±197* (37% > URL) |
| Cortisol after dexamethasone (nmol/l) | |
| - SCS | 145±131 (92% > URL) |
| - CCS | 296±183* (95% > URL) |
| ACTH (pmol/l) | |
| - SCS | 1.47±0.92 (39% nd) |
| - CCS | 0.85±0.89 (85% nd) |
SCS: subclinical Cushing’s syndrome, CCS: clinical Cushing’s syndrome, URL: upper reference limit, nd: non-detectable, data presented as mean±SD, *P<0.05, compared to SCS. ¶ ACTH levels below the lower detection limit of 1.10 pmol/l were set at 0.55 pmol/l.
response to hormonal stimuli in patients with AIMAH
| ACTH1-24 | 29 | - | 28 (97%) |
| Posture | 26 | 4 (15%) | 13 (50%) |
| Salt loading | 6 | 1 (17%) | 1 (17%) |
| AVP | 21 | 6 (29%) | 12 (52%) |
| Metoclopramide | 29 | 3 (10%) | 7 (24%) |
| LHRH | 30 | 5 (17%) | 5 (17%) |
| TRH | 29 | 2 (7 %) | 3 (10%) |
| Glucagon | 26 | 4 (15%) | 4 (15%) |
| Mixed meal | 32 | 2 (6%) | 6 (18%) |
| Number of aberrant responses | n | n | |
| 0 | | 20 | 8 |
| 1 | | 8 | 10 |
| 2 | | 4 | 11 |
| 3 | | 3 | 5 |
| 4 | 0 | 1 | |
Figure 1and induction of cortisol production following administration of hormonal stimuli. (A) Patients were tested for the presence of aberrant expression of eutopic or ectopic hormone receptors by the administration of hormonal stimuli in various tests indicated on the X-axis. Line represents mean. *p<0.05, **p<0.01, ***p<0.001 compared to basal level (Wilcoxon signed rank test). (B) Primary cell cultures from AIMAH tissues (white bars) or from normal adrenals, ACTH-dependent adrenocortical hyperplasia or adenomas (other, black bars) were incubated for 2 h in the presence of specific hormone receptor agonists indicated on the X-axis. Concentrations used have been summarized in Table 3. Data are represented as mean+SEM. *p<0.05, **p<0.01, ***p<0.001 compared to vehicle control (Wilcoxon signed rank) or between pathological entities (Mann–Whitney U test). (C) Cortisol induction in media of AIMAH or other adrenal cells after 48 h incubation with specific hormone receptor agonists. Concentrations used are summarized in Table 4. Data are represented as mean+SEM. *p<0.05 compared to vehicle control (Wilcoxon signed rank). Numbers of patients are shown in Tables 2, 3 and 4.
Two hour cortisol responses to hormonal stimuli in primary adrenal cell cultures
| | | | ||||||
|---|---|---|---|---|---|---|---|---|
| ACTH1-24 | 50 pg/ml | 7 | 2 (29%) | 4 (57%) | 0.30 | 5 | 1 (20%) | 4 (80%) |
| ACTH1-24 | 500 pg/ml | 10 | 3 (30%) | 6 (60%) | 0.07 | 18 | 1 (6%) | 16 (89%) |
| FSK | 1 μM | 8 | 0 | 7 (88%) | 0.29 | 9 | 0 | 7 (78%) |
| AngII | 10 nM | 2 | 0 | 0 | n.a. # | 2 | 1 (50%) | 1 (50%) |
| AVP | 10 nM | 6 | 2 (33%) | 1 (17%) | −0.72†; -0.50# | 4 | 1 (25%) | 0 |
| AVP | 100 nM | 4 | 1 (25%) | 1 (25%) | −1.00†; -0.80# | 3 | 1 (33%) | 0 |
| Desmopressin | 10 nM | 5 | 0 | 0 | −0.80 | 3 | 0 | 0 |
| Metoclopramide | 1 μM | 7 | 0 | 2 (29%) | 0.71 | 14 | 3 (21%) | 0 |
| Epinephrine | 1 μM | 7 | 1 (14%) | 1 (14%) | −0.50# | 5 | 0 | 0 |
| Norepinephrine | 1 μM | 7 | 1 (14%) | 0 | −0.15# | 5 | 0 | 0 |
| hCG | 100 IU/ml | 10 | 3 (30%) | 0 | 0.60 | 4 | 0 | 0 |
| TSH | 10 nM | 4 | 0 | 0 | −0.32 | 1 | 0 | 0 |
| Glucagon | 1 μM | 4 | 0 | 0 | 0.50 | 1 | 0 | 0 |
| GIP | 100 nM | 6 | 1 (17%) | 1 (17%) | 0.49¶ | 4 | 1 (25%) | 0 |
¶ standard mixed meal, # upright posture test, † AVP im, n.a.: not applicable.
Forty-eight hour cortisol responses to hormonal stimuli in AIMAH cells
| ACTH1-24 | 10 ng/ml | 7 | 0 | 6 (86%) | −0.39 | 0.20 |
| AngII | 100 nM | 4 | 0 | 4 (100%) | 1.00**# | n.a. |
| AVP | 10 nM | 3 | 0 | 2 (67%) | 0.50†; n.a.# | n.a. |
| AVP | 100 nM | 7 | 1 (14%) | 6 (86%) | −0.18†; -0.086# | −0.50 |
| Desmopressin | 10 nM | 5 | 0 | 0 | −0.67 | 1.00** |
| Metoclopramide | 1 μM | 4 | 0 | 2 (50%) | 0.60 | 1.00** |
| Norepinephrine | 1 μM | 4 | 0 | 0 | −0.50# | −0.50# |
| hCG | 100 IU/ml | 4 | 0 | 0 | −0.60 | −0.50 |
| TSH | 10 nM | 2 | 0 | 1 (50%) | n.a. | n.a. |
| Glucagon | 1 μM | 4 | 0 | 0 | −0.20 | n.a. |
| GIP | 100 nM | 2 | 0 | 0 | −1.00¶ | n.a. |
**p<0.01, ¶ standard mixed meal, # upright posture test, † AVP im, n.a. not applicable.
Figure 2Induction of and steroidogenic enzyme mRNAs following addition of hormonal stimuli. Primary cell cultures from AIMAH tissues (white bars) or from normal adrenals, ACTH-dependent adrenocortical hyperplasia, adenomas or carcinomas (other, black bars) were incubated for 48 hours in the presence of hormones depicted on X-axis. Concentrations used are summarized in Table 4. The mRNA levels of STAR, CYP11A1, HSD3B2, CYP17A1, CYP21A2 and CYP11B1 were studied by quantitative RT-PCR and calculated relative to HPRT1 expression. Data are represented as mean+SEM. *p<0.05, **p<0.01, compared to basal level (Wilcoxon signed rank) or between pathological entities (Mann–Whitney U test).
Figure 3AVP receptor expression in adrenal tissues. (A) AVP type 1a receptor (V1, AVPR1A) mRNA expression in human adrenocortical tissues (Nl: normal, Hyp: ACTH-dependent hyperplasia, ADA: adrenocortical adenoma, ACC: adrenocortical carcinoma), measured by qRT-PCR. R.U.: relative units, compared to HPRT1 expression. *p<0.05, Kruskal-Wallis test. V2 and V3 receptor expression levels were extremely low or undetectable. (B) Significant correlation between AVPR1A expression levels and the induction of CYP11B1 by 100 nM AVP after 48 hours in cultures of primary cells of adrenal tissues. Corresponding icons for individual tissue groups are depicted in Figure A and B.